Thalidomide

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
US
  • Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL)
Product first approved 1998Outside this platform's coveragedailymed.nlm.nih.gov
EU
  • Thalidomide (now Thalidomide BMS) with melphalan and prednisone, first-line untreated multiple myeloma, age >=65 or ineligible for high-dose chemotherapy
Product first approved 2008EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (69)
Multiple Myeloma
NCT00098475 · National Cancer Institute (NCI)
2004-11-03 – 2027-10-21 · DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
What this study did
NCT00572169 · University of Arkansas
2006-11 – 2027-08 · Multiple Myeloma
What this study did
NCT03562169 · University of Leeds
2017-03-20 – 2027-03 · Multiple Myeloma
What this study did
NCT02541383 · Intergroupe Francophone du Myelome
2015-09 – 2023-09-01 · Multiple Myeloma
What this study did
NCT01554852 · University of Leeds
2010-05 – 2022-12 · Multiple Myeloma
What this study did
NCT02248428 · Jinling Hospital, China
2012-04 – 2020-09 · Multiple Myeloma
What this study did
NCT01539083 · Janssen Scientific Affairs, LLC
2012-01-13 – 2018-01-09 · Multiple Myeloma
What this study did
NCT00892346 · Shanghai Jiao Tong University School of Medicine
2009-05 – 2017-12 · Multiple Myeloma
What this study did
NCT03402295 · Grupo de Estudos Multicentricos em Onco-Hematologia
2009-06-15 – 2017-10-15 · Multiple Myeloma, Effects of Chemotherapy
What this study did
NCT00256776 · European Society for Blood and Marrow Transplantation
2005-07 – 2015-12 · Multiple Myeloma
What this study did
NCT00232934 · Gruppo Italiano per lo Studio del Mieloma Multiplo
2002-01 – 2014-11 · Multiple Myeloma
What this study did
NCT01063179 · Fondazione EMN Italy Onlus
2006-05 – 2014-07 · Multiple Myeloma
What this study did
NCT00049673 · NCIC Clinical Trials Group
2002-10-15 – 2013-09-19 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00028886 · Commissie Voor Klinisch Toegepast Onderzoek
started 2001-03 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00057564 · Celgene Corporation
2003-02 – 2013-08 · Multiple Myeloma
What this study did
NCT00507416 · Millennium Pharmaceuticals, Inc.
2007-06 – 2013-03 · Multiple Myeloma
What this study did
NCT00075829 · National Heart, Lung, and Blood Institute (NHLBI)
2003-12 – 2013-03 · Multiple Myeloma
What this study did
NCT00934154 · Cigdem Sahinbas YILMAZ
2006-03 – 2012-09 · Multiple Myeloma
What this study did
NCT00215943 · H. Lee Moffitt Cancer Center and Research Institute
2003-06 – 2012-08 · Multiple Myeloma
What this study did
NCT01532856 · Grupo de Estudos Multicentricos em Onco-Hematologia
2007-01 – 2012-06 · Multiple Myeloma
What this study did
NCT00432458 · Mayo Clinic
2003-07 – 2012-04 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00574080 · University of Arkansas
2006-07 – 2011-03 · Multiple Myeloma
What this study did
NCT00602511 · Nordic Myeloma Study Group
2007-10 – 2010-12 · Multiple Myeloma
What this study did
NCT01296503 · Grupo de Estudos Multicentricos em Onco-Hematologia
2003-10 – 2010-12 · Multiple Myeloma
What this study did
NCT00222053 · University Hospital, Toulouse
2000-04 – 2009-12 · Multiple Myeloma
What this study did
NCT00443235 · PETHEMA Foundation
2005-03 – 2009-12 · Multiple Myeloma
What this study did
NCT00097981 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2005-01 – 2009-10 · Multiple Myeloma
What this study did
NCT00910897 · Intergroupe Francophone du Myelome
2008-03 – 2009-08 · Multiple Myeloma
What this study did
NCT00452569 · Celgene
2006-02-01 – 2009-01-01 · Multiple Myeloma
What this study did
NCT00461747 · PETHEMA Foundation
2006-03 – 2008-12 · Multiple Myeloma
What this study did
NCT00573391 · University of Arkansas
2006-08 – 2008-07 · Multiple Myeloma
What this study did
NCT00005834 · SWOG Cancer Research Network
2000-04 – 2007-11 · Multiple Myeloma
What this study did
NCT00633542 · Università Politecnica delle Marche
2003-06 – 2007-10 · Multiple Myeloma
What this study did
NCT00644306 · Central Hospital, Nancy, France
2002-04 – 2007-05 · Newly Diagnosed, Multiple Myeloma
What this study did
NCT00218855 · Norwegian University of Science and Technology
2002-01 – 2007-04 · Multiple Myeloma
What this study did
NCT00111748 · University of Arkansas
2005-02 – 2006-09 · Multiple Myeloma
What this study did
NCT00033332 · National Cancer Institute (NCI)
2002-04 – 2006-06 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00367185 · University Hospital, Lille
2000-05 – 2005-10 · Multiple Myeloma
What this study did
NCT00038233 · M.D. Anderson Cancer Center
1999-05 – 2005-04 · Multiple Myeloma
What this study did
Other / comorbidity
NCT06017284 · Fudan University
2023-11-01 – 2026-11-30 · Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
What this study did
NCT06031012 · Air Force Military Medical University, China
2023-09-15 – 2025-10-31 · Mucositis Oral
What this study did
NCT03016000 · Nanfang Hospital, Southern Medical University
2017-07-26 – 2023-12 · Lymphoma, Large B-Cell, Diffuse
What this study did
NCT06146478 · Blood Care Clinic
2022-01-25 – 2023-10-31 · Transfusion-dependent Beta-Thalassemia
What this study did
NCT02085655 · Huiqiang Huang
2013-04-25 – 2022-12-31 · Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
What this study did
NCT02707484 · Shanghai Jiao Tong University School of Medicine
2016-04 – 2021-04 · Gastrointestinal Vascular Malformation
What this study did
Phase 2/3 (13)
Multiple Myeloma
NCT03759093 · National University Hospital, Singapore
2023-09-10 – 2025-09-10 · Multiple Myeloma
What this study did
NCT00205751 · Austrian Forum Against Cancer
2001-08 – 2009-10 · Multiple Myeloma
What this study did
NCT00657488 · Celgene
2001-12-01 – 2006-04-01 · Multiple Myeloma
What this study did
NCT00038090 · M.D. Anderson Cancer Center
2000-06 – 2005-05 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07309419 · Shanghai Zhongshan Hospital
2025-12-22 – 2030-06-30 · Hepatocellular Carcinoma
What this study did
NCT04453345 · Institute of Hematology & Blood Diseases Hospital, China
2013-05-20 – 2025-05-20 · T-LGL Leukemia, Clpd-Nk
What this study did
NCT06153784 · Children's Hospital Karachi
2020-07-07 – 2023-07-30 · Thalassemia, Beta
What this study did
NCT03651102 · Blood Diseases Clinic
2018-01-01 – 2022-03-01 · Thalassemia
What this study did
NCT05132270 · Children's Hospital Karachi
2020-01-01 – 2021-01-31 · Thalassemia, Beta
What this study did
NCT02387086 · Bai Jun
2015-05 – 2017-05 · NSCLC
What this study did
NCT01094340 · Banner Health
2010-03 – 2013-01 · Alzheimer's Disease
What this study did
NCT00934739 · National Health Research Institutes, Taiwan
2007-06 – 2012-12 · Oral Cavity Cancer
What this study did
NCT00728078 · Sun Yat-sen University
2008-07 – 2011-07 · Hepatocellular Carcinoma, Liver Cancer
What this study did
Phase 2 (219)
Multiple Myeloma
NCT00869232 · University of Arkansas
2008-10 – 2028-10 · Multiple Myeloma
What this study did
NCT03004287 · University of Arkansas
2017-07-01 – 2028-10 · Multiple Myeloma
What this study did
NCT04941937 · Juan Du
2022-01-27 – 2025-12-30 · Multiple Myeloma
What this study did
NCT02891811 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2017-03-10 – 2024-03-28 · Multiple Myeloma
What this study did
NCT04352205 · Emory University
2020-05-07 – 2024-01-19 · Plasma Cell Myeloma, Renal Failure
What this study did
NCT03140943 · National University Hospital, Singapore
2017-09-13 – 2022-06-01 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT00777998 · Universitätsklinikum Hamburg-Eppendorf
2008-10-14 – 2021-06 · Multiple Myeloma
What this study did
NCT01849783 · Margarida Magalhaes-Silverman
2013-04-04 – 2020-09-30 · Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT00538733 · Weill Medical College of Cornell University
2007-10 – 2020-09-17 · Multiple Myeloma
What this study did
NCT02424851 · Oxford University Hospitals NHS Trust
2014-11 – 2020-04-20 · Multiple Myeloma, Chronic Kidney Disease
What this study did
NCT02410694 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2015-04 – 2019-05-02 · Multiple Myeloma
What this study did
NCT00004088 · City of Hope Medical Center
1999-07-08 – 2018-01-09 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT01526694 · Azienda Ospedaliera di Bolzano
2012-07 – 2017-04-08 · Multiple Myeloma
What this study did
NCT00961467 · Fondazione EMN Italy Onlus
2007-02 – 2016-04 · Multiple Myeloma
What this study did
NCT01632150 · Bristol-Myers Squibb
2012-05 – 2016-03 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT00064337 · SWOG Cancer Research Network
2004-01 – 2015-11 · Multiple Myeloma, Plasma Cell Myeloma
What this study did
NCT00040937 · SWOG Cancer Research Network
2002-06 – 2015-10 · Multiple Myeloma
What this study did
NCT00081939 · University of Arkansas
2004-01 – 2014-09 · Multiple Myeloma
What this study did
NCT01548573 · University of Iowa
2012-05 – 2014-08 · Multiple Myeloma
What this study did
NCT00083382 · University of Arkansas
1998-12 – 2014-05 · Multiple Myeloma
What this study did
NCT00792142 · City of Hope Medical Center
2008-03-08 – 2014-04-21 · Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
What this study did
NCT00112879 · The Cleveland Clinic
— · Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
What this study did
NCT00523848 · Roswell Park Cancer Institute
2006-06 – 2012-10 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT01114048 · Chonnam National University Hospital
2010-03 – 2012-03 · Multiple Myeloma
What this study did
NCT01055301 · SWOG Cancer Research Network
2011-07 – 2011-07 · Multiple Myeloma, Plasma Cell Myeloma
What this study did
NCT00458705 · Memorial Sloan Kettering Cancer Center
2006-11 – 2011-04 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00124813 · University Hospital, Bonn
2002-08 – 2010-11 · Multiple Myeloma
What this study did
NCT00287872 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2004-09 – 2010-11 · Multiple Myeloma
What this study did
NCT00263484 · Gleneagles Hospital
2005-12 – 2010-10 · Multiple Myeloma
What this study did
NCT00538824 · Weill Medical College of Cornell University
2007-12 – 2010-09-22 · Multiple Myeloma
What this study did
NCT00124579 · SWOG Cancer Research Network
2005-08 – 2010-06 · Multiple Myeloma
What this study did
NCT00222105 · University of Kansas Medical Center
2002-11 – 2009-07 · Multiple Myeloma
What this study did
NCT00531453 · Millennium Pharmaceuticals, Inc.
2007-10 – 2009-05 · Multiple Myeloma
What this study did
NCT00577668 · University of Arkansas
2007-04 – 2009-04 · Multiple Myeloma
What this study did
NCT00193544 · SCRI Development Innovations, LLC
2002-03 – 2009-01 · Multiple Myeloma
What this study did
NCT01341262 · IRCCS Azienda Ospedaliero-Universitaria di Bologna
2002-03 – 2009-01 · Multiple Myeloma
What this study did
NCT00006890 · NCIC Clinical Trials Group
2000-07-12 – 2008-12-15 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00358020 · University of Turin, Italy
2004-11 – 2008-12 · Multiple Myeloma
What this study did
NCT00438841 · Fred Hutchinson Cancer Center
2006-08 – 2008-12 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00319865 · Korean Multiple Myeloma Working Party
2005-11 – 2008-09 · Multiple Myeloma
What this study did
NCT00349115 · Korean Multiple Myeloma Working Party
2006-06 – 2008-06 · Multiple Myeloma
What this study did
NCT00083538 · University of Arkansas
2001-02 – 2007-12 · Multiple Myeloma
What this study did
NCT00089167 · Memorial Sloan Kettering Cancer Center
2002-05 – 2007-12 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00182663 · Fred Hutchinson Cancer Center
2003-06 – 2007-04 · Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT00022607 · California Cancer Consortium
2002-01 – 2006-05 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00054158 · Roswell Park Cancer Institute
2004-08 – 2006-04 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00227682 · OHSU Knight Cancer Institute
2004-06 – 2006-02 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
Phase 1/2 (16)
Multiple Myeloma
NCT04891744 · Li Zheng
2021-07-06 – 2024-12-30 · Multiple Myeloma
What this study did
NCT00966693 · M.D. Anderson Cancer Center
2009-08-25 – 2018-07-20 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT01057225 · Mayo Clinic
2010-03 – 2017-09-05 · Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT01242267 · Hackensack Meridian Health
2010-05-11 – 2016-01-20 · Multiple Myeloma
What this study did
NCT02145715 · Prof Jamie Cavenagh
2013-01 – 2016-01 · Multiple Myeloma
What this study did
NCT00406978 · Silvio Aime
2006-02 – 2014-04 · Multiple Myeloma
What this study did
NCT00081757 · University of Arkansas
1998-09 – 2005-05 · Multiple Myeloma
What this study did
Other / comorbidity
NCT05198856 · Qilu Hospital of Shandong University
2022-03-10 – 2024-12-10 · Gastric Cancer Metastatic to Liver
What this study did
NCT02545907 · University College, London
2017-09-14 – 2019-10-21 · Amyloidosis
What this study did
NCT00096018 · Roswell Park Cancer Institute
2002-05 – 2012-05 · Leukemia
What this study did
NCT00971126 · National Health Research Institutes, Taiwan
2009-07 – 2010-03 · Hepatocellular Carcinoma
What this study did
NCT01061866 · National Institute of Neurology and Neurosurgery, Mexico
2006-06 – 2008-01 · Refractory Epilepsy
What this study did
NCT00155272 · National Taiwan University Hospital
2005-03 – 2005-08 · Hepatocellular Carcinoma
What this study did
NCT00277017 · New Mexico Cancer Research Alliance
2000-09 – 2005-08 · Kidney, Cancer
What this study did
NCT00038246 · M.D. Anderson Cancer Center
2000-10 – 2004-12 · Prostate Cancer
What this study did
NCT00005815 · Memorial Sloan Kettering Cancer Center
1999-12 – 2004-08 · Intraocular Melanoma, Melanoma (Skin)
What this study did
Phase 1 (19)
Multiple Myeloma
NCT01998971 · Janssen Research & Development, LLC
2014-02-18 – 2024-01-11 · Multiple Myeloma
What this study did
NCT02467647 · Wuhan University
2015-01 – 2019-12 · Multiple Myeloma
What this study did
NCT01937442 · Celgene
2013-11-07 – 2015-09-23 · Multiple Myeloma
What this study did
NCT01537861 · Washington University School of Medicine
2012-06 – 2014-12 · Multiple Myeloma
What this study did
NCT00258245 · Barbara Ann Karmanos Cancer Institute
2005-05 – 2008-04 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00083460 · University of Arkansas
2001-12 – 2007-11 · Multiple Myeloma
What this study did
Other / comorbidity
NCT06098014 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-03-01 – 2024-02-28 · Transfusion-dependent Thalassemia
What this study did
NCT01661400 · Washington University School of Medicine
2012-10-26 – 2023-12-27 · Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Retinoblastoma
What this study did
NCT02870036 · Haihe Biopharma Co., Ltd.
2016-10 – 2020-12 · Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
What this study did
NCT02956538 · Sixth Affiliated Hospital, Sun Yat-sen University
2016-10 – 2018-10 · Crohn Disease
What this study did
NCT00527657 · M.D. Anderson Cancer Center
2006-02-09 – 2012-02-02 · Brain Neoplasms, Melanoma
What this study did
NCT01028781 · University of North Carolina, Chapel Hill
2006-10 – 2009-08 · Endometriosis
What this study did
NCT00418132 · NYU Langone Health
2000-08 – 2007-10 · Scleroderma, Systemic
What this study did
NCT00251797 · University of New Mexico
2000-03 – 2006-06 · Brain and Nervous System, Cancer
What this study did
NCT00062127 · National Cancer Institute (NCI)
2003-04 – 2006-05 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00049296 · Case Comprehensive Cancer Center
2002-07 – 2006-01 · Cancer
What this study did
NCT00002104 · Aaron Diamond AIDS Research Center
— · Mycobacterium Avium-Intracellulare Infection, HIV Infections, Tuberculosis, Mycobacterium Infection
What this study did
NCT00052416 · Beth Israel Deaconess Medical Center
2002-10 – 2003-01 · Leukemia, Lymphoma
What this study did
NCT00000812 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2000-07 · HIV Infections
What this study did
Phase 4 (18)
Multiple Myeloma
NCT02559154 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2010-07 – 2018-12 · Multiple Myeloma
What this study did
NCT01249690 · Second Military Medical University
2010-06 – 2014-06 · Multiple Myeloma
What this study did
Other / comorbidity
NCT06276933 · Tongji University
2024-02-22 – 2026-11-22 · Lung Cancer, Camrelizumab
What this study did
NCT06299670 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-11-01 – 2026-01-30 · Transfusion-dependent Thalassemia
What this study did
NCT05527444 · Qilu Hospital of Shandong University
2022-03-15 – 2024-12-31 · Ankylosing Spondylitis
What this study did
NCT04612582 · Guangdong Provincial People's Hospital
2020-01-01 – 2023-06-30 · Immunoglobulin Light-Chain Amyloidosis
What this study did
NCT05525234 · RenJi Hospital
2022-09-15 – 2023-01-31 · Haemodialysis, Uremic Pruritus, Thalidomide
What this study did
NCT03777930 · Shenzhen Fifth People's Hospital
2018-12-10 – 2021-06-10 · Cancer, Therapy-Related
What this study did
NCT03122431 · University of Sao Paulo General Hospital
2017-06-05 – 2021-03-30 · Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus
What this study did
NCT02858804 · Institute of Hematology & Blood Diseases Hospital, China
2016-01 – 2020-06 · Mantle Cell Lymphoma
What this study did
NCT02844309 · Institute of Hematology & Blood Diseases Hospital, China
2016-05 – 2020-05 · Waldenström Macroglobulinemia
What this study did
NCT02778893 · Henan Provincial People's Hospital
2016-03 – 2020-03 · NSCLC
What this study did
NCT02401971 · Wang Jufeng
2014-08 – 2018-08 · Gastric Cancer
What this study did
NCT01638078 · University of Roma La Sapienza
2014-01 – 2017-12 · Coronary Artery Disease
What this study did
NCT01640639 · University of Roma La Sapienza
2012-07 – 2014-12 · Congestive Heart Failure
What this study did
NCT00390247 · Chinese University of Hong Kong
2007-01 – 2008-12 · Peritoneal Dialysis, Malnutrition
What this study did
NCT00314665 · University of Cincinnati
2004-01 – 2006-08 · Uveitis
What this study did
Early phase / not applicable (20)
Multiple Myeloma
NCT06793475 · Institute of Hematology & Blood Diseases Hospital, China
2025-04-09 – 2026-12 · Extramedullary Multiple Myeloma
What this study did
NCT00023530 · National Heart, Lung, and Blood Institute (NHLBI)
2001-09 – 2006-08 · Bone Marrow Transplantation, Blood Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Graft vs Host Disease
What this study did
NCT00577096 · University of Arkansas
2001-10 – 2004-06 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07933653 · First Affiliated Hospital of Guangxi Medical University
2026-11-12 – 2028-12-31 · Radiodermatitis, Breast Neoplasms
What this study did
NCT07476625 · Wenjie Zheng
2026-04-01 – 2028-03-30 · Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis Syndrome
What this study did
NCT07673302 · Riphah International University
2026-06-20 – 2027-06-19 · Thalassemia
What this study did
NCT06256627 · Henan Cancer Hospital
2023-07-11 – 2027-05-01 · Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b, Interleukin-2, Thalidomide, Venentoclax, Azacitidine
What this study did
NCT06772480 · Institute of Liver and Biliary Sciences, India
2025-01-05 – 2026-01-31 · Liver Cirrhosis, Gastric Antral Vascular Ectasia
What this study did
NCT06888232 · Muhammad Aamir Latif
2023-08-01 – 2024-12-31 · Thalassemia
What this study did
NCT05059613 · Jiangxi Provincial Cancer Hospital
2021-09-20 – 2022-12-31 · Oral Mucositis, Quality of Life
What this study did
NCT03601871 · Yunpeng Liu
2018-07-12 – 2020-12-30 · Chemotherapy-induced Nausea and Vomiting
What this study did
NCT01924624 · The First Affiliated Hospital of Xiamen University
2013-07 – 2019-12 · Hepatocellular Carcinoma, Recurrence
What this study did
NCT02998827 · Sixth Affiliated Hospital, Sun Yat-sen University
2016-11 – 2017-11 · Crohn Disease
What this study did
NCT01927718 · M.D. Anderson Cancer Center
2014-01 – 2016-11 · Myeloma
What this study did
NCT00907452 · Intergroupe Francophone du Myelome
2009-07-29 – 2016-07-14 · Myeloma
What this study did
NCT00769587 · Centre Hospitalier Universitaire, Amiens
2007-06 – 2012-10 · Non Neoplastic Condition, Precancerous Condition
What this study did
NCT00002174 · Louisiana State University Health Sciences Center in New Orleans
— · HIV Infections
What this study did
NCT00002157 · Celgene Corporation
— · HIV Infections, HIV Wasting Syndrome
What this study did
NCT00002392 · Rockefeller University
— · HIV Infections
What this study did
NCT00004450 · FDA Office of Orphan Products Development
1998-08 – 2000-11 · Adrenoleukodystrophy
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Multiple Myeloma
NCT00602641 · National Cancer Institute (NCI)
2008-02-29 – 2027-02-20 · Multiple Myeloma
What this study did
Other / comorbidity
NCT01659658 · Millennium Pharmaceuticals, Inc.
2012-12-26 – 2022-07-11 · Relapsed or Refractory Systemic Light Chain Amyloidosis
What this study did
Phase 2 (6)
Multiple Myeloma
NCT03896737 · European Myeloma Network B.V.
2019-04-16 – 2027-09-15 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07828015 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-05-01 – 2029-09-01 · Bevacizimab, HHT
What this study did
NCT07172659 · Medicines Development for Global Health
2026-10-12 – 2028-07 · Erythema Nodosum Leprosum
What this study did
NCT06239389 · National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
2021-09-01 – 2022-03-03 · Beta-Thalassemia
What this study did
NCT03204032 · Chinese Academy of Medical Sciences
2016-10 – 2018-09 · Extrapancreatic Neuroendocrine Tumor
What this study did
NCT03204019 · Chinese Academy of Medical Sciences
2016-10 – 2018-09 · Pancreatic Neuroendocrine Tumor
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (1)
Multiple Myeloma
NCT00083876 · University of Arkansas
1998-09 – 2007-11 · Multiple Myeloma
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Other / comorbidity
NCT07884773 · Khyber Medical University Peshawar
2026-10-12 – 2027-05-20 · Beta-Thalassemia, Thalassemia
What this study did
Phase 2 (2)
Other / comorbidity
NCT00121563 · National Institute of Nursing Research (NINR)
2005-07 – 2006-02 · Pain
What this study did
NCT00001475 · National Institute of Allergy and Infectious Diseases (NIAID)
1995-06 – 2002-06 · Acquired Immunodeficiency Syndrome, HIV Infection
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Thalidomide: this drugApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BelantamabPhase 1/2Monoclonal antibodyBCMAnot yet gradedNo reviewed efficacy summary in this indication
CT071Phase 1/2Cell therapyGPRC5Dnot yet gradedNo reviewed efficacy summary in this indication
EltanexorPhase 1/2—XPO1 (exportin-1)Weak signalNo reviewed efficacy summary in this indication
ICP-490Phase 1/2Small moleculeCereblon E3 ubiquitin-ligaseWeak signalNo reviewed efficacy summary in this indication
TQB3820
Phase 1(overall)
Small moleculeCereblon E3 ubiquitin-ligase, Cereblon E3 ubiquitin-ligaseWeak signalNo reviewed efficacy summary in this indication

Large race: only the 66 furthest-along competitors are listed; 101 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Thalidomide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (12)
February 2027 (2)
Phase 2Syringomyelia, ThalidomideRecruiting
Est. primary completion 2027-02 · NCT06268093 · CT.gov ↗
What to watch
Phase 2MyelofibrosisActive not recruiting
Est. primary completion 2027-02 · NCT03069326 · CT.gov ↗
What to watch
March 2027 (1)
Early phase / not applicablePeriodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis SyndromeNot yet recruiting
Est. primary completion 2027-03-31 · NCT07476625 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Langerhans Cell HistiocytosisRecruiting
Est. primary completion 2027-04-12 · NCT07187193 · CT.gov ↗
What to watch
June 2027 (1)
Early phase / not applicableThalassemiaRecruiting
Est. primary completion 2027-06-19 · NCT07673302 · CT.gov ↗
What to watch
August 2027 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT00572169 · CT.gov ↗
What to watch
Phase 2Langerhans Cell Histiocytosis (LCH)Active not recruiting
Est. primary completion 2027-08-01 · NCT07204041 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT00869232 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT03004287 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT00871013 · CT.gov ↗
What to watch
Phase 2Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT07195799 · CT.gov ↗
What to watch
Phase 2Transfusion-dependent β-thalassemia PatientsRecruiting
Est. primary completion 2027-12-31 · NCT07338344 · CT.gov ↗
What to watch
2028 (3)
June 2028 (1)
Early phase / not applicableRadiodermatitis, Breast NeoplasmsRecruiting
Est. primary completion 2028-06-30 · NCT07933653 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Peripheral T-Cell LymphomaNot yet recruiting
Est. primary completion 2028-07-31 · NCT07746245 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Radiation EnteritisRecruiting
Est. primary completion 2028-10-01 · NCT06617182 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 2Solid Tumor CancerRecruiting
Est. primary completion 2029-06 · NCT07671534 · CT.gov ↗
What to watch
2030 (2)
April 2030 (1)
Phase 2Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor RecurrentRecruiting
Est. primary completion 2030-04 · NCT01356290 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2/3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2030-06-30 · NCT07309419 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

September 2026ApprovalFDA updates Boxed Warning on Thalidomide (NDA020785)
US, FDA · FDA · Source ↗